AG
SLDB icon

Artal Group’s Solid Biosciences SLDB Stock Holding History

Artal Group’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,500,000
Closed -$14.2M – 84
2024
Q2 		$14.2M Hold
2,500,000
– – 0.36% 31
2024
Q1 		$33.3M Buy
2,500,000
+1,590,781
+175% +$14.9M 0.85% 18
2023
Q4 		$5.58M Hold
909,219
– – 0.19% 48
2023
Q3 		$2.29M Hold
909,219
– – 0.1% 66
2023
Q2 		$4.76M Hold
909,219
– – 0.15% 68
2023
Q1 		$4.31M Hold
909,219
– – 0.26% 65
2022
Q4 		$4.89M Buy
909,219
+709,219
+355% +$4.65M 0.27% 63
2022
Q3 		$1.4M Hold
200,000
– – 0.06% 101
2022
Q2 		$1.85M Hold
200,000
– – 0.1% 101
2022
Q1 		$3.6M Hold
200,000
– – 0.15% 93
2021
Q4 		$5.25M Hold
200,000
– – 0.14% 101
2021
Q3 		$7.17M Buy
200,000
+50,000
+33% +$2.12M 0.16% 98
2021
Q2 		$8.23M Hold
150,000
– – 0.17% 98
2021
Q1 		$12.4M Buy
+150,000
New +$16.6M 0.22% 89
2020
Q4 		– Sell
-114,000
Closed -$3.47M – 153
2020
Q3 		$3.47M Sell
114,000
-6,000
-5% -$230K 0.08% 110
2020
Q2 		$5.27M Hold
120,000
– – 0.15% 103
2020
Q1 		$4.3M Hold
120,000
– – 0.18% 79
2019
Q4 		$8.01M Buy
120,000
+6,667
+6% +$736K 0.31% 56
2019
Q3 		$17.6M Buy
113,333
+33,333
+42% +$3.77M 0.7% 27
2019
Q2 		$6.9M Hold
80,000
– – 0.28% 69
2019
Q1 		$11M Buy
80,000
+46,667
+140% +$11.7M 0.45% 46
2018
Q4 		$13.4M Buy
33,333
+18,333
+122% +$8.62M 0.5% 36
2018
Q3 		$10.6M Sell
15,000
-1,667
-10% -$1.05M 0.28% 53
2018
Q2 		$8.91M Buy
16,667
+6,667
+67% +$2.05M 0.19% 52
2018
Q1 		$1.13M Buy
+10,000
New +$3.38M 0.01% 103

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artal Group's SLDB Position: Q3 2024 in Review

Artal Group sold out of Solid Biosciences (SLDB) in Q3 2024, closing a stake of 2,500,000 shares — an estimated $14.2M sold.

Artal Group first reported a position in SLDB in Q1 2018 and held it in 25 quarters. The position peaked at $33.3M in Q1 2024. 92 funds tracked by Wall St. Rank hold SLDB as of Q3 2024.

  • Artal Group reported no remaining Solid Biosciences position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 2,500,000 Solid Biosciences shares in Q3 2024, an estimated $14.2M.
  • Artal Group first reported a position in Solid Biosciences in Q1 2018 and held it in 25 quarters.
  • Artal Group's Solid Biosciences position peaked at $33.3M in Q1 2024.
  • 92 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.